{"schema_version":"1.0","type":"article","title":"百靈佳73.6億美元押中國新藥，台灣先輸在賣什麼","url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.md","lang":"zh-Hant","date":"2026-11-09","publish_at":"2026-11-09T08:00:00+08:00","updated_at":"2026-11-09","category":"商業分析系列","topic":"商業分析系列","tags":["授權交易","百靈佳殷格翰","中國生物製藥","ADC","台灣生技"],"summary":"百靈佳殷格翰 11 月 4 日向中國生物製藥買下 6 個臨床前 ADC 與 T 細胞接合器，帳面最高約 73.6 億美元、首付 3.58 億美元；台灣 2026 年 9 筆對外授權公開總額約 8.3 億美元，唯一公開首付 1,000 萬美元。差距有兩層：台灣賣的多是改良型新藥、生物相似藥與單一國家權利；就算是新一代平台，韓國首付仍只有中國同類案的約九分之一，買方付錢買的是臨床數據規模。","key_points":["百靈佳殷格翰 2026 年 11 月 4 日與中國生物製藥簽下 6 個臨床前 ADC 與 T 細胞接合器授權，首付與近期款項 3.58 億美元，帳面總值最高約 73.6 億美元。","台灣上市櫃生技 2026 年 1 月至 10 月公告 9 筆對外授權，6 筆為改良型新藥或生物相似藥，8 筆只授權一個國家或區域，唯一公開首付為 1,000 萬美元，資產結構是第一道天花板。","禮來 2025 年付韓國 ABL Bio 平台首付 4,000 萬美元、2026 年 2 月付中國信達生物 3.5 億美元；Evaluate 統計全球 ADC 臨床試驗 51% 來自中國公司，臨床數據規模是第二道門檻。"],"facts":[{"claim":"百靈佳殷格翰與中國生物製藥授權案公告日","value":"2026-11-04","unit":"date","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"百靈佳付給中國生物製藥的首付與近期款項","value":358,"unit":"百萬美元","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"選擇權、開發、法規與銷售里程碑金上限","value":7000,"unit":"百萬美元","as_of":"2026-11-04","source":"Boehringer Ingelheim 2026-11-04"},{"claim":"授權計畫數（ADC 與 T 細胞接合器，臨床前）","value":6,"unit":"個","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"6 個計畫中授權中國大陸、香港、澳門以外權利者","value":4,"unit":"個","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"中國生物製藥收購禮新醫藥其餘 95.09% 股權價金上限（2025 年 7 月）","value":951,"unit":"百萬美元","as_of":"2026-11-04","source":"BioPharm International 2026-11-04"},{"claim":"中國對外授權平均首付（Evaluate）2022 年","value":52,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"中國對外授權平均首付（Evaluate）2026 年","value":170,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"韓國 2026 上半年 8 筆技術輸出首付上限","value":"<50","unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"禮來付給信達生物首付（2026 年 2 月）","value":350,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"台灣上市櫃生技 2026-01-05 至 2026-10-15 公告對外授權筆數","value":9,"unit":"筆","as_of":"2026-11-03","source":"藥時事 台灣生技授權交易總表 2026-11-03"},{"claim":"逸達授權 Primevera 首付","value":10,"unit":"百萬美元","as_of":"2026-01-08","source":"PR Newswire 2026-01-08"},{"claim":"逸達授權 Primevera 里程碑金上限","value":574.5,"unit":"百萬美元","as_of":"2026-01-08","source":"PR Newswire 2026-01-08"},{"claim":"台微體 TLC599 日本授權總額上限","value":203,"unit":"百萬美元","as_of":"2026-10-05","source":"公開資訊觀測站 2026-10-05"},{"claim":"台康生技 EG1206A 日本授權總額","value":1320,"unit":"百萬新台幣","as_of":"2026-06-29","source":"公開資訊觀測站 2026-06-29"},{"claim":"BioNTech 收購普米斯生物首付","value":800,"unit":"百萬美元","as_of":"2024-11-13","source":"BioNTech 2024-11-13"},{"claim":"BioNTech 收購普米斯生物里程碑金上限","value":150,"unit":"百萬美元","as_of":"2024-11-13","source":"BioNTech 2024-11-13"},{"claim":"BMS 付給 BioNTech 的 pumitamig 首付","value":1500,"unit":"百萬美元","as_of":"2025-06-02","source":"BioSpace 2025-06-02"},{"claim":"BMS 至 2028 年前付給 BioNTech 的非條件款","value":2000,"unit":"百萬美元","as_of":"2025-06-02","source":"BioSpace 2025-06-02"},{"claim":"pumitamig 進行中的樞紐試驗數","value":7,"unit":"個","as_of":"2026-11-03","source":"BioNTech 2026-11-03"},{"claim":"禮來付韓國 ABL Bio 平台授權首付（2025 年）","value":40,"unit":"百萬美元","as_of":"2026-06-16","source":"The Asia Business Daily 2026-06-16"},{"claim":"全球 ADC 臨床試驗中來自中國公司產品的比例（Evaluate）","value":51,"unit":"%","as_of":"2026-02-27","source":"Fierce Biotech 2026-02"},{"claim":"全球 CAR-T 臨床試驗中中國的比例（Evaluate）","value":48,"unit":"%","as_of":"2026-02-27","source":"Fierce Biotech 2026-02"}],"sections":["01｜73.6 億美元拆開，先拿到手的是 3.58 億","02｜同一把尺量首付：中國、韓國、台灣","03｜台灣今年賣出去的是什麼","04｜第二層：韓國有新平台，首付還是差九倍","05｜同一顆藥，誰賺到倍數","06｜反方說法：中國那些數字多半領不到","07｜台灣要拿到同級首付，要過哪兩關","參考資料"],"references":[{"title":"Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies","source":"Boehringer Ingelheim","date":"2026-11-04","url":"https://www.boehringer-ingelheim.com/human-health/boehringer-announces-new-oncology-partnership-sbp-group"},{"title":"Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion","source":"BioPharm International","date":"2026-11-04","url":"https://www.biopharminternational.com/view/boehringer-ingelheim-licenses-six-preclinical-adc-and-t-cell-engager-programs-from-sbp-group-in-deal-worth-up-to-7-billion"},{"title":"[KR-China Bio Contrast] Despite Similar Promising Technologies, Upfront Payments Are Only One-Third of China's","source":"The Asia Business Daily","date":"2026-06-16","url":"https://view.asiae.co.kr/en/article/2026060908060639753"},{"title":"After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst（Evaluate 分析師 Mark Lansdell","source":"Fierce Biotech","date":"","url":"https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions"},{"title":"BioNTech to Acquire Biotheus","source":"BioNTech（SEC Form 6-K","date":"2024-11-13","url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698524000094/a99_1biontechtoacquirebiot.htm"},{"title":"BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific","source":"BioSpace","date":"2025-06-02","url":"https://www.biospace.com/deals/bms-commits-up-to-11b-to-work-with-biontech-on-solid-tumor-bispecific"},{"title":"BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update","source":"BioNTech","date":"2026-11-03","url":"https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2026/11/BioNTech-Announces-Third-Quarter-2026-Financial-Results-and-Corporate-Update.html"},{"title":"Foresee Pharmaceuticals Announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics","source":"PR Newswire","date":"2026-01-08","url":"https://www.prnewswire.co.uk/news-releases/foresee-pharmaceuticals-announces-global-licensing-agreement-for-mmp-12-inhibitors-with-primevera-therapeutics-llc-302656280.html"},{"title":"台微體 TLC599 日本授權重大訊息","source":"公開資訊觀測站","date":"2026-10-05","url":"https://mops.twse.com.tw/mops/#/web/t05st01?companyId=7924&marketKind=rotc&enterDate=1151005&serialNumber=1"},{"title":"台康生技 EG1206A 日本授權重大訊息","source":"公開資訊觀測站","date":"2026-06-29","url":"https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6589&marketKind=sii&enterDate=1150629&serialNumber=2"},{"title":"台灣生技授權交易總表","source":"藥時事","date":"2026-11-03","url":"https://drugnews.com.tw/taiwan-licensing-deals.html"}],"images":[{"alt":"圖1｜73.6 億美元裡，先到手的是 3.58 億","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/figure-01.png"},{"alt":"圖2｜同一把尺：首付金額比較","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/figure-02.png"},{"alt":"圖3｜台灣 2026 年 9 筆對外授權：資產類型與授權範圍","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/figure-03.png"},{"alt":"圖4｜同一顆藥的兩次交易","url":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-09）。百靈佳73.6億美元押中國新藥，台灣先輸在賣什麼。https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}